



Egyptian Journal of Chemistry

<http://ejchem.journals.ekb.eg/>



Physiology of Glucose: An Updated Review for Healthcare Professionals.

Hanadi Naji Alhajrasi¹, Maryam Helal Rasheed Alanazi¹, Hamoud Ghayyadh Alanizi¹, Amal Khalifah Almutairi¹, Khaled Abdul Rahman Suleiman Al-Rashudi¹, Khalid Saeed Oudah Alahmari², Meshal Mahdi Abdulrahman Alshehri², Shatha Ahmed Alhefdhi², Mohammed Ali Ibrahim Bakri¹, Wafa Saadullah Saleh¹, Anan Homoud Alhazmi¹, Ali Abdullah Mohammed Alajlan¹, Ahmad Asri Awad Alanazi¹, Adel Lafi Alharbi¹, Bander Nasser Alharbi¹, Naif Abdulrahman Al-Azmi¹, Ohud Ahmed Ahmed², Saad Abdulrazaq Ahmed Hayjan¹

¹ Ministry of National Guard, Saudi Arabia

² King Khalid University Hospital, Saudi Arabia

Abstract

Background: Glucose is the dominant carbohydrate fuel that supports cellular respiration, with availability sustained by coordinated digestion, intestinal absorption, hepatic processing, storage as glycogen, and regulated tissue uptake. Disruption of these processes produces clinically significant dysglycemia.

Aim: To synthesize contemporary physiological concepts of glucose handling across molecular, cellular, and organ-system levels, and to link these mechanisms to diagnostic testing and clinical states relevant to healthcare practice.

Methods: Narrative integration of established mechanisms of glucose metabolism (glycolysis, tricarboxylic acid cycle, oxidative phosphorylation), storage dynamics, transporter biology (SGLT/GLUT families), endocrine regulation (insulin and counter-regulatory hormones), and standard glycemic tests (FBG, RBG, OGTT), with pathophysiologic correlates.

Results: Glucose flux is determined by (1) cellular pathways converting glucose to ATP under anaerobic and aerobic conditions; (2) storage-mobilization cycles governed by insulin-glucagon signaling; (3) tissue-specific transport via SGLTs and GLUT isoforms, notably insulin-responsive GLUT-4; and (4) organ axes—liver, pancreas, adrenal, thyroid, and anterior pituitary—that integrate nutrient and stress cues. Diagnostic assays (FBG, RBG, OGTT) characterize fasting and dynamic regulation, enabling detection of impaired tolerance and diabetes. Perturbations manifest as type 1 diabetes (autoimmune insulin deficiency), type 2 diabetes (insulin resistance with β -cell dysfunction), reactive and fasting hypoglycemia, and metabolic syndrome. Chronic hyperglycemia drives micro- and macrovascular complications; acute crises include hyperosmolar hyperglycemic state, while hypoglycemia endangers neurocognitive function.

Conclusion: Glucose homeostasis emerges from tightly coupled transport, enzymatic, and endocrine controls. Understanding these interactions improves risk stratification, testing choices, and targeted interventions across the dysglycemia spectrum.

Keywords: glucose physiology; glycogen; SGLT; GLUT-4; insulin; glucagon; gluconeogenesis; oral glucose tolerance test; metabolic syndrome; type 1 diabetes; type 2 diabetes; hypoglycemia; hyperosmolar hyperglycemic state.

1. Introduction

Glucose is a six-carbon monosaccharide (hexose) with the empirical formula $C_6H_{12}O_6$. As a central representative of the carbohydrate class, it exemplifies the ubiquitous biological role of carbohydrates as primary energetic substrates across virtually all domains of life. In both simple and complex organisms, carbohydrates furnish the reducing equivalents and carbon skeletons that sustain cellular respiration under aerobic and anaerobic conditions, thereby underpinning organismal energetics and metabolic homeostasis [1]. In the human diet, glucose is introduced not only in its free form but also as structural isomers such as galactose and fructose (monosaccharides), as components of disaccharides including lactose and sucrose, and within polymeric reserves such as starch (polysaccharides). When intake exceeds immediate energetic demand, surplus glucose is conserved as glycogen—an α -1,4/ α -1,6-linked polymer of glucose—strategically stored (predominantly in liver and muscle) for mobilization during fasting or heightened energy requirements. Complementing exogenous supply, endogenous glucose can be synthesized de novo via gluconeogenesis, a biosynthetic pathway that recruits non-carbohydrate precursors derived from lipid and protein catabolism to reconstitute the circulating glucose pool [2]. Owing to this paramount physiological importance, multiple dietary and metabolic routes converge to maintain adequate glucose availability compatible with systemic homeostatic set-points. Once present within the internal milieu, the glucose molecule is conveyed by the bloodstream to tissues with current energetic demand, where it is taken up and routed into coordinated catabolic cascades [3]. Through these sequential biochemical transformations, the chemical potential embodied in glucose's carbon-hydrogen bonds is transduced into adenosine triphosphate (ATP), the universal energy currency that powers mechanical work, active transport, biosynthesis, and myriad other energy-requiring processes in living cells. In eukaryotic systems, the preponderance of ATP is generated by oxygen-dependent (aerobic)

*Corresponding author e-mail ayman.mukui@gmail.com (Ayman Mohammed Mukui)

Receive Date: 19 July 2025, Revise Date: 17 September 2025, Accept Date: 02 October 2025

DOI: 10.21608/ejchem.2025.405197.12065

©2025 National Information and Documentation Center (NIDOC)

Beyond governing polymer metabolism, insulin and glucagon shape cellular glucose flux. Insulin increases the capacity of peripheral tissues, especially adipose and muscle—to import glucose by augmenting the presence and function of glucose transporter type 4 (GLUT-4) at the plasma membrane, primarily through stimulus-dependent vesicular translocation and longer-term effects on gene expression. Glucagon, conversely, restrains hepatic glucose uptake and indirectly diminishes peripheral uptake by opposing insulin-dependent pathways. In sum, the coordinated, hormone-driven regulation of glycogen synthesis and degradation, coupled with precisely controlled glucose transport, constitutes a nimble system that preserves metabolic homeostasis across feeding–fasting cycles. This cellular choreography ensures efficient storage in times of plenty and reliable glucose provisioning when exogenous supply wanes, with GLUT-4-mediated transport serving as a critical effector of insulin’s action in target tissues [6][7].

Glucose Transporters

Glucose entry into cells is mediated by a family of specialized membrane proteins whose distribution and kinetics are tailored to the metabolic demands of individual tissues. Broadly, these carriers fall into two mechanistic classes: sodium-dependent glucose transporters (SGLTs) and sodium-independent glucose transporters (GLUTs). SGLTs are co-transporters that harness the energy stored in a transmembrane sodium gradient to drive glucose uptake against its concentration gradient—a paradigm of secondary active transport. By contrast, GLUT proteins operate via facilitated diffusion, enabling glucose to equilibrate across the plasma membrane down its electrochemical gradient without direct coupling to ion fluxes. Among the sodium-independent transporters, only GLUT4 demonstrates pronounced hormonal regulation by insulin and glucagon at the level of expression and membrane availability, rendering it uniquely sensitive to the organism’s nutritional state (see Image. Glucose Transporters).




Figure 2: Glucose Transporters.

SGLTs are concentrated in epithelia dedicated to nutrient reclamation and uptake—most notably the renal proximal tubule and the intestinal mucosa. Their function depends on the Na^+/K^+ -ATPase, which continuously expels sodium from the cell into the interstitial space at the expense of ATP, thereby establishing a steep inward sodium gradient. The SGLT situated on the apical (luminal) membrane couples the downhill movement of Na^+ into the cytosol with the uphill co-transport of glucose, effectively accumulating glucose within the epithelial cell. This arrangement permits efficient absorption of dietary carbohydrate in the gut and near-complete reabsorption of filtered glucose in the kidney, preventing caloric loss and safeguarding systemic energy balance. The GLUT family comprises several isoforms with distinct tissue distributions and physiological roles. GLUT-1 is found at high levels in pancreatic β -cells, erythrocytes, and hepatocytes. Operating bidirectionally, this transporter contributes to pancreatic glucose sensing, a critical component of the feedback circuitry that aligns endogenous insulin secretion with prevailing glycemia. Its presence in red blood cells ensures continuous glucose supply to support anaerobic metabolism, while hepatic expression aids in modulating hepatic glucose handling in accordance with portal blood glucose concentrations.

GLUT-2 is enriched in hepatocytes, pancreatic β -cells, intestinal epithelium, and renal tubular cells. Characterized by bidirectional flux and capacity suited to large glucose loads, GLUT-2 is pivotal for hepatic carbohydrate homeostasis, facilitating both uptake during postprandial states and release during fasting. In enterocytes and renal epithelia, GLUT-2 often resides on the basolateral membrane, exporting intracellular glucose into the bloodstream following apical SGLT-mediated entry, thereby integrating transcellular transport from lumen to circulation. GLUT-3 predominates in the central nervous system and is distinguished by a high affinity for glucose. This kinetic profile aligns with the brain’s continuous and substantial metabolic demand, ensuring neuronal glucose availability even when extracellular concentrations decline. The CNS reliance on GLUT-3 underscores the priority accorded to cerebral energetics in systemic fuel allocation.

GLUT-4 is most abundant in skeletal muscle, cardiac muscle, adipose tissue, and selected brain regions. Under basal conditions, GLUT-4 remains sequestered within intracellular vesicles, rendering the cell surface relatively impermeable to glucose. Insulin stimulation triggers a rapid signaling cascade that mobilizes these vesicles to fuse with the plasma membrane, markedly augmenting surface GLUT-4 abundance. During states of nutrient plenty and elevated insulin, membrane GLUT-4 density can rise by approximately 10- to 20-fold, dramatically enhancing cellular glucose uptake and thereby reducing circulating glucose concentrations. This translocation response is complemented by longer-term adjustments in GLUT-4 expression, integrating acute and chronic hormonal cues. The physiological consequence is a robust capacity of muscle and adipose tissue to buffer postprandial hyperglycemia, while defects in GLUT-4 trafficking or expression contribute materially to insulin resistance. In sum, the tissue-specific expression of SGLTs and GLUTs, coupled with the dynamic, hormone-sensitive regulation of GLUT-4, creates a finely tuned network that matches glucose flux to cellular and systemic energetic needs, maintaining glycemic homeostasis across feeding–fasting cycles [8][9][10][11].

Organ Systems Involved

Glucose underpins the normal performance of virtually every organ system; nevertheless, a subset of organs assumes primary responsibility for sensing, buffering, and restoring circulating glucose to its physiological range. These organs operate as an integrated endocrine–metabolic axis that anticipates nutritional status, orchestrates substrate flux, and allocates fuel to tissues with differing and sometimes competing demands.

Liver

The liver is the central node of blood glucose regulation. It houses one of the body's principal carbohydrate depots in the form of glycogen—a highly branched polymer of glucose that, together with skeletal muscle stores, provides a rapidly mobilizable reservoir. Whereas triacylglycerol stored in adipocytes constitutes the dominant long-term energy reserve, hepatic (and muscle) glycogen serves short-term buffering functions, stabilizing plasma glucose between meals and during acute energy expenditure. In fasting states or whenever glucagon predominates, hepatocytes accelerate glycogenolysis, releasing glucose to the circulation and thereby elevating blood glucose concentrations. In contrast, during nutrient abundance with insulin signaling in the ascendant, the liver channels glucose into glycogenesis, expanding glycogen stores and lowering glycemia. Through this bidirectional control—glycogen breakdown under glucagon and synthesis under insulin—the liver continuously titrates glucose output to match systemic requirements [13].




Figure 3: Insulin Effects and Organs Involved.

Pancreas

The endocrine pancreas provides the principal hormonal actuators of glycemic control. When glucose rises within pancreatic β -cells, these cells secrete insulin, initiating a suite of processes that collectively diminish blood glucose. These include stimulation of glucose uptake in insulin-responsive tissues, promotion of glycogen synthesis, and redirection of intermediary metabolism toward storage pathways. Conversely, when circulating glucose falls and β -cell insulin secretion wanes, α -cells release glucagon, which counteracts hypoglycemia by stimulating hepatic glycogenolysis and gluconeogenesis. A further layer of modulation derives from somatostatin secreted by γ -cells of the islets, which exerts an overall glucose-lowering influence by restraining both insulin and glucagon release and tempering gastrointestinal contributions to postprandial glycemia. Together, these hormones enable the pancreas to sense prevailing nutrient status and implement rapid, coordinated adjustments in glucose production and utilization [14][15][16].

Adrenal Gland

Both regions of the adrenal gland contribute to glucose homeostasis through distinct hormonal outputs. The adrenal cortex secretes glucocorticoids, most notably cortisol—which increase blood glucose by fostering hepatic glucose production

and by shifting peripheral metabolism toward substrate mobilization, effects that are especially salient during prolonged fasting or physiological stress. The adrenal medulla releases epinephrine (adrenaline), a catecholamine that promptly elevates plasma glucose during acute stress by mechanisms that include stimulation of hepatic glucose release and reallocation of energy substrates. In concert, cortical and medullary signals reinforce the capacity of the organism to defend glycemia during stress, illness, or sudden increases in energy demand [17].

Thyroid Gland

The thyroid gland produces and secretes thyroxine, a hormone with pervasive effects on cellular metabolism. By broadly increasing basal metabolic rate and modulating the expression and activity of myriad metabolic enzymes, thyroxine indirectly elevates blood glucose. Its systemic actions enhance carbohydrate turnover across tissues, thereby influencing both glucose utilization and the compensatory mechanisms that sustain adequate circulating levels during periods of heightened metabolic activity [18].

Anterior Pituitary Gland

The anterior pituitary augments this regulatory network through the secretion of adrenocorticotrophic hormone (ACTH) and growth hormone (GH). ACTH drives adrenal cortical production of glucocorticoids, indirectly supporting hyperglycemic responses under conditions of stress or fasting. Growth hormone, via its counter-regulatory actions, promotes increases in blood glucose by reducing insulin-mediated glucose uptake in certain tissues and by favoring lipolysis, thereby sparing glucose for obligate users. The combined influence of ACTH and GH thus contributes to the maintenance of euglycemia, particularly when catabolic demands or stressors challenge carbohydrate reserves [19]. In aggregate, the liver, pancreas, adrenal glands, thyroid, and anterior pituitary operate as a tightly coupled control system. By integrating nutrient cues with hormonal outputs, they balance storage with mobilization and consumption with conservation, ensuring that glucose supply remains commensurate with the moment-to-moment needs of the organism.

Hormones

Glucose homeostasis is governed by a coordinated endocrine network in which multiple hormones exert complementary or antagonistic effects on hepatic output, peripheral uptake, and intestinal handling of carbohydrate. From a practical standpoint, the regulatory schema can be remembered by grouping the actors into glucose-lowering agents—principally insulin and, in net effect, somatostatin—and glucose-raising, “counter-regulatory” hormones, which include glucagon, cortisol, epinephrine, thyroxine, growth hormone, and adrenocorticotrophic hormone (ACTH). Appreciating each hormone’s signaling logic and integrated outcome clarifies how the organism maintains euglycemia across feeding–fasting cycles, exercise, stress, and illness.

Insulin lowers circulating glucose through complementary actions on transport, storage, and gene expression. In insulin-responsive tissues (skeletal muscle, adipose, and heart), insulin augments GLUT4 availability at the plasma membrane and supports its longer-term expression, thereby accelerating cellular glucose influx. Hepatically, insulin promotes glycogenesis by upregulating glycogen synthase activity—partly via dephosphorylation cascades—and simultaneously restrains catabolic enzymes by inactivating phosphorylase kinase, which curtails glycogen breakdown and limits hepatic glucose output. At the transcriptional level, insulin suppresses key gluconeogenic drivers, diminishing the expression of rate-limiting enzymes and thereby reducing endogenous glucose production. The net result is a decisive fall in plasma glucose.

Glucagon is the principal hyperglycemic counterweight to insulin. Secreted by pancreatic α -cells during fasting or hypoglycemia, glucagon engages cAMP–protein kinase A signaling in hepatocytes to stimulate glycogenolysis and to upregulate gluconeogenesis. By accelerating release of hepatic glucose into the circulation while attenuating hepatic glucose uptake, glucagon restores glycemia when exogenous supply is limited.

Somatostatin exerts a nuanced, yet overall glucose-lowering, influence. Produced by pancreatic γ -cells, it locally inhibits glucagon secretion and moderates pituitary tropic hormones and gastrin, thereby tempering counter-regulatory drives and gastrointestinal contributions to postprandial glycemia. Although somatostatin also suppresses insulin release, the aggregate effect—by dampening glucagon and digestive hormone tone—is a reduction in blood glucose levels.

Cortisol, the dominant glucocorticoid of the adrenal cortex, increases plasma glucose by promoting hepatic gluconeogenesis and by antagonizing insulin action in peripheral tissues. It mobilizes amino acids from muscle and enhances lipolysis, supplying substrates (alanine, glycerol) for hepatic glucose production while diminishing insulin-mediated glucose uptake. These effects become especially salient during prolonged fasting, chronic stress, and inflammatory states.

Epinephrine, released from the adrenal medulla during acute stress, rapidly elevates glucose through several mechanisms. It activates hepatic glycogen phosphorylase to drive glycogenolysis and enhances glucagon release while restraining insulin secretion, thereby favoring hepatic glucose export. In adipose tissue, epinephrine stimulates lipolysis, increasing circulating fatty acids and glycerol; the latter enters gluconeogenic pathways, further supporting hyperglycemia. In skeletal muscle, epinephrine accelerates glycogenolysis to meet local energy demands, with lactate generated for hepatic reconversion to glucose via the Cori cycle.

Thyroxine (T4) raises blood glucose by increasing basal metabolic rate and modulating carbohydrate turnover. It facilitates intestinal glucose absorption and encourages hepatic glycogenolysis, while broad transcriptional effects remodel enzyme expression toward heightened substrate flux. The cumulative impact is an upward shift in glucose appearance in the circulation during states of thyroid hormone excess.

Growth hormone (GH) functions as a counter-regulatory hormone by promoting gluconeogenesis, reducing hepatic glucose uptake, and opposing insulin’s actions in certain peripheral tissues. GH also interacts with the thyroid axis, supporting thyroid hormone activity and, indirectly, carbohydrate mobilization. Concomitantly, GH stimulates lipolysis, increasing availability of fatty acids and glycerol, thereby sparing glucose for obligate consumers and supplying gluconeogenic precursors.

Adrenocorticotrophic hormone (ACTH), secreted by the anterior pituitary, acts primarily by stimulating adrenal cortisol production, thereby amplifying glucocorticoid-mediated increases in hepatic glucose output. ACTH also promotes mobilization of fatty acids from adipose tissue, expanding the pool of substrates that feed gluconeogenesis and reinforcing the systemic hyperglycemic response. Collectively, these hormones form an adaptable control system that integrates nutrient cues with stress and circadian inputs. Insulin (and, in net, somatostatin) biases the system toward storage and efficient disposal of

postprandial glucose, whereas glucagon, cortisol, epinephrine, thyroxine, GH, and ACTH mobilize endogenous reserves and favor hepatic production when exogenous supply wanes. The continuous, reciprocal modulation among these signals maintains glucose within a narrow physiological window despite fluctuating environmental and metabolic demands [20].

Table 1. Hormones Regulating Glycemia: Sources, Mechanisms, Net Effects.

Hormone	Primary source	Key targets/mechanisms	Net effect on plasma glucose
Insulin	Pancreatic β -cells	$\uparrow$ GLUT-4 translocation; $\uparrow$ glycogenesis; $\downarrow$ glycogenolysis; $\downarrow$ gluconeogenesis	Decrease
Glucagon	Pancreatic α -cells	$\uparrow$ Hepatic glycogenolysis and gluconeogenesis	Increase
Somatostatin	Pancreatic γ/δ -cells	$\downarrow$ Glucagon and insulin; $\downarrow$ GI hormones; slows nutrient flux	Net decrease
Epinephrine	Adrenal medulla	$\uparrow$ Hepatic glycogenolysis; $\uparrow$ lipolysis; $\downarrow$ insulin secretion	Increase
Cortisol	Adrenal cortex	$\uparrow$ Gluconeogenesis; insulin antagonism; protein catabolism	Increase
Thyroxine (T4)	Thyroid gland	$\uparrow$ Basal metabolic rate; $\uparrow$ intestinal absorption; $\uparrow$ glycogenolysis	Increase
Growth hormone (GH)	Anterior pituitary	Insulin antagonism; $\uparrow$ lipolysis; $\uparrow$ gluconeogenesis	Increase
ACTH	Anterior pituitary	$\uparrow$ Cortisol synthesis; mobilizes fatty acids	Increase (indirect)

Related Testing

Fasting Blood Glucose Test

The fasting blood glucose (FBG) assay is a foundational measure of glycemia obtained after a minimum of 8 hours without caloric intake, typically drawn prior to breakfast to ensure true fasting conditions. Specimens are analyzed in plasma or serum using validated enzymatic methodologies or high-throughput automated analyzers to quantify glucose concentration with analytic precision appropriate for clinical decision-making. Under standard reference intervals, normative fasting values are generally 70 to 100 mg/dL (3.9 to 5.6 mmol/L) [21]. Because the FBG reflects basal hepatic glucose output and insulin-mediated restraint of that output, it serves as a sensitive screen for disturbances in fasting homeostasis and as a comparator for dynamic tests that interrogate postprandial regulation.

Random Blood Glucose Testing

Random blood glucose (RBG) testing provides an immediate appraisal of glycemic status without the need for prior fasting or scheduling, thereby enabling rapid assessment in urgent, opportunistic, or ambulatory settings. Measurement can be performed at the point of care with a calibrated glucometer or in a clinical laboratory via standard biochemical assays, each reporting the instantaneous circulating glucose concentration. Unlike fasting indices or structured tolerance testing, RBG offers a snapshot that is particularly useful when symptoms suggest dysglycemia or when timely triage is required. In individuals without diabetes mellitus, reference values typically span 70 to 140 mg/dL (3.9 to 7.8 mmol/L) [22]. Laboratories may apply slightly different reference intervals, and interpretation should account for methodological differences and patient-specific variables (e.g., recent dietary intake, stress, intercurrent illness) that can modulate random measurements [23]. When markedly elevated, an RBG can strongly suggest diabetes in the appropriate clinical context and may prompt confirmatory fasting or tolerance testing.

Oral Glucose Tolerance Test

The oral glucose tolerance test (OGTT) is a standardized dynamic evaluation of glucose handling that interrogates the integrated response of intestinal absorption, pancreatic insulin secretion, hepatic glucose production, and peripheral glucose uptake. It is particularly informative for detecting early dysglycemia—both diabetes and pre-diabetes—thus enabling preventive interventions to mitigate progression and complications. After an overnight fast, a 75-g anhydrous glucose load is administered orally, followed by serial venous sampling at prespecified intervals, commonly at baseline (0 minutes) and at 30, 60, 90, and 120 minutes post-ingestion. Quantification of plasma glucose across this time course characterizes the body's capacity to accommodate a defined glycemic challenge [24][25].

Normal Response

In persons with normal glucose tolerance, plasma glucose rises transiently after the glucose load and then declines to approximate fasting levels within 2 hours. Such a pattern indicates prompt insulin release, efficient suppression of hepatic glucose output, and effective peripheral disposal, collectively reflecting intact glucose metabolism.

Impaired Glucose Tolerance

Impaired glucose tolerance (IGT) is defined by elevated glucose values during the OGTT that exceed normal thresholds yet fall short of diagnostic criteria for diabetes mellitus. IGT represents an intermediate state of dysglycemia associated with increased risk for progression to overt diabetes and heightened cardiovascular morbidity. Identification of IGT provides a critical window for targeted lifestyle and, when appropriate, pharmacologic interventions.

Table 2. Common Glycemic Tests: Protocols, Reference Ranges, and Clinical Utility.

Test	Core protocol	Reference range (adults)	Principal clinical use
Fasting Blood Glucose (FBG)	Venous sample after ≥ 8 h fast	70–100 mg/dL (3.9–5.6 mmol/L)	Screen basal regulation; compare with dynamic tests
Random Blood Glucose (RBG)	Point-in-time sample without fasting	~ 70 –140 mg/dL (3.9–7.8 mmol/L) in non-diabetics*	Rapid assessment/triage; symptomatic evaluation
Oral Glucose Tolerance Test (OGTT)	75 g oral load; samples at 0–120 min	2-h < 140 mg/dL normal; 140–199 mg/dL impaired; ≥ 200 mg/dL diabetes	Detect IGT/diabetes; gestational diabetes diagnosis

Diabetes Mellitus

Diabetes mellitus is diagnosed when the OGTT demonstrates persistent hyperglycemia, specifically a fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L) or a 2-hour post-load value ≥ 200 mg/dL (11.1 mmol/L) on two separate occasions. These thresholds anchor the classification of disordered glucose regulation and guide subsequent management strategies. The OGTT holds particular clinical value in the diagnosis of gestational diabetes mellitus, a transient diabetogenic state of pregnancy that carries implications for maternal and fetal outcomes and often necessitates tailored monitoring and therapy [26]. In aggregate, FBG, RBG, and OGTT constitute complementary modalities that span the spectrum from basal to dynamic assessment of glucose homeostasis. Used judiciously and interpreted within methodological and clinical context, these tests enable precise characterization of glycemic status, early detection of pathology, and evidence-based risk stratification and follow-up.

Pathophysiology

Glucose metabolism is maintained by interdependent hormonal and cellular programs that align ATP generation with moment-to-moment energy demand while averting excursions into hyperglycemia or hypoglycemia. Hepatic glucose production, pancreatic islet signaling, peripheral uptake in muscle and adipose tissue, and autonomic inputs form a closed-loop network that continuously recalibrates flux across feeding–fasting cycles, exercise, illness, and stress. Breakdown of any node destabilizes this equilibrium and precipitates dysglycemia—ranging from transient disturbances to chronic metabolic disease—underscoring why mechanistic insight into disordered regulation is central to prevention and treatment [27]. **Type 1 diabetes.** Type 1 diabetes results from autoimmune destruction of pancreatic β -cells, culminating in absolute insulin deficiency. In the absence of insulin, skeletal muscle and adipose tissue fail to recruit GLUT4 to the plasma membrane, hepatic gluconeogenesis and glycogenolysis proceed unchecked, and adipose lipolysis accelerates with excess ketone formation. The clinical picture combines persistent hyperglycemia, osmotic diuresis and dehydration, weight loss, and a propensity for diabetic ketoacidosis. Physiologic insulin replacement restores peripheral glucose disposal, restrains hepatic glucose output, and suppresses ketogenesis, thereby re-establishing core elements of metabolic homeostasis.

Type 2 diabetes. Type 2 diabetes arises primarily from insulin resistance superimposed on progressive β -cell dysfunction. Early in the disease, compensatory hyperinsulinemia masks resistance in liver and muscle; with time, glucotoxicity, lipotoxicity, oxidative stress, and islet amyloid deposition erode β -cell mass and secretory capacity. Hepatic gluconeogenesis remains inappropriately elevated, skeletal muscle glucose uptake is blunted, and adipose tissue releases greater quantities of non-esterified fatty acids that further impair insulin signaling. The resulting hyperglycemia becomes self-reinforcing, driving a cycle of metabolic stress and β -cell exhaustion.

Reactive hypoglycemia. Reactive (postprandial) hypoglycemia reflects an exaggerated insulin response to carbohydrate-rich meals. Rapid intestinal absorption provokes disproportionate insulin secretion relative to the actual glycemic load, accelerating plasma glucose disposal and producing a symptomatic nadir one to three hours after eating. Autonomic manifestations (tremor, palpitations) and neuroglycopenic symptoms (fatigue, confusion) track transient cerebral fuel deprivation. Dietary strategies—lower-glycemic-index foods, mixed macronutrient composition, and smaller, more frequent meals—often mitigate these episodes.

Fasting hypoglycemia. Hypoglycemia during fasting signals failure of endogenous defenses that normally sustain glucose between meals. Causes include deficiencies of counter-regulatory hormones (e.g., adrenal insufficiency or hypopituitarism), hepatic disorders that limit glycogen storage or gluconeogenesis, and enzymatic defects that impair glycogenolysis or gluconeogenic pathways. The shared pathophysiology is inadequate endogenous glucose production relative to central nervous system demand, particularly during prolonged caloric deprivation or intercurrent illness.

Metabolic syndrome. Metabolic syndrome comprises central obesity, insulin resistance, atherogenic dyslipidemia, and hypertension—a clustering that markedly elevates risk for atherosclerotic cardiovascular disease and type 2 diabetes. Insulin resistance sits at the mechanistic core: in muscle it depresses glucose uptake; in liver it sustains gluconeogenesis and drives very-low-density lipoprotein overproduction; in adipose tissue it promotes lipolysis, inflammation, and ectopic lipid deposition in liver and muscle. Adipocyte hypertrophy and altered adipokine secretion amplify systemic insulin resistance and endothelial dysfunction, linking disordered glucose handling to vascular disease. Collectively, these abnormalities integrate into a feed-forward loop in which impaired insulin action destabilizes both glucose and lipid metabolism, thereby accelerating cardiometabolic risk and progression to overt diabetes [28][29][30].

Clinical Significance

Glucose-related pathology arises when circulating levels drift outside the physiologic range, producing injury at both the hyperglycemic and hypoglycemic extremes. Among these disturbances, chronic hyperglycemia accounts for much of the global burden of disease, driving acute decompensations as well as the cumulative, organ-level damage that underlies long-term morbidity. Type 1 and type 2 diabetes epitomize sustained hyperglycemia in which elevated glucose is central to pathogenesis and outcomes [31]. Type 1 diabetes reflects autoimmune destruction of pancreatic β -cells, culminating in absolute insulin deficiency; it frequently presents in childhood or adolescence and is shaped by genetic, environmental, and immunologic influences. Type 2 diabetes, by contrast, is dominated by peripheral insulin resistance—often in the context of obesity and other cardiometabolic comorbidities—superimposed on progressive β -cell dysfunction; it classically manifests in adulthood and is

likewise modulated by inherited susceptibility. Despite their distinct origins, both syndromes share a final common pathway: inappropriately elevated blood glucose that perturbs cellular homeostasis and damages tissues over time [31]. Several mechanisms couple chronic hyperglycemia to tissue injury. First, **osmotic stress**: glucose is strongly osmotically active, and sustained elevation distorts water balance across membranes in susceptible compartments, contributing to peripheral nerve damage and other cellular dysfunctions. Second, **oxidative stress**: excessive glucose flux accelerates reactions that generate reactive oxygen and nitrogen species, overwhelming antioxidant defenses and damaging lipids, proteins, and nucleic acids. Third, **non-enzymatic glycation**: reducing sugars, including glucose, covalently modify lysine residues on long-lived proteins, altering structure and function; advanced glycation end-products further amplify inflammation and stiffness within tissues [32][6]. These processes converge to produce the characteristic complications of diabetes. On the **microvascular** side, consequences include retinopathy with vision loss, nephropathy progressing to chronic kidney disease, and distal symmetric polyneuropathy with pain, loss of protective sensation, and autonomic involvement. On the **macrovascular** side, accelerated atherosclerosis manifests as coronary artery disease and ischemic cerebrovascular disease. Impaired leukocyte function, reduced perfusion, and neuropathy together drive poor wound healing and chronic, nonhealing ulcers, particularly in the lower extremities. Recognition of these mechanistic links underscores why meticulous glycemic control, cardiovascular risk reduction, and surveillance for end-organ sequelae are essential elements of care [33][34].

Hyperglycemia can also precipitate acute, life-threatening decompensation. A prototypical emergency—seen most commonly in type 2 diabetes—is the **hyperosmolar hyperglycemic state (HHS)**. In HHS, extreme plasma glucose concentrations raise effective osmolality, shifting water from intracellular to extracellular compartments and provoking profound osmotic diuresis. The ensuing polyuria drives substantial electrolyte loss and severe dehydration. Clinically, patients may present with altered mental status, focal or global neurologic deficits, motor abnormalities, orthostatic hypotension, nausea, vomiting, and abdominal pain. Prompt recognition and treatment—centered on vigorous fluid resuscitation, careful electrolyte correction, and targeted insulin therapy—are critical to reversing the metabolic derangements and preventing complications [35]. Although the focus here is hyperglycemia, **hypoglycemia** is also clinically consequential: sudden or sustained reductions in plasma glucose jeopardize cerebral metabolism, provoking adrenergic symptoms (tremor, palpitations, diaphoresis) and neuroglycopenic features (confusion, seizures, coma). Together, these bidirectional hazards highlight the importance of vigilant monitoring and individualized therapeutic targets to maintain glucose within a safe, functional range across diverse clinical contexts.

Hypoglycemia

Hypoglycemia most frequently arises as an iatrogenic consequence of glucose-lowering therapies in individuals with diabetes mellitus. The risk is particularly pronounced in hospitalized settings, where routine meals or usual dietary patterns are interrupted, altering the balance between exogenous carbohydrate intake and pharmacologic insulin action. Because the clinical presentation is often nonspecific, diagnostic confidence increases when symptoms correlate with fasting or exertion and remit promptly after carbohydrate administration—features that heighten the pretest probability of low blood glucose as the underlying cause [36]. Clinically, manifestations are grouped into two mechanistic categories. **Neuroglycopenic** symptoms reflect insufficient glucose delivery to the central nervous system and encompass fatigue, irritability or behavioral changes, seizures, and, in severe cases, coma or death. **Neurogenic** symptoms arise from activation of the sympatho-adrenergic system in response to falling glucose and split into adrenergic and cholinergic phenotypes: the **adrenergic** cluster typically includes anxiety, tremulousness, and palpitations, whereas the **cholinergic** cluster features paresthesias, diaphoresis, and intense hunger [37]. Recognizing these patterns helps distinguish hypoglycemia from mimicking conditions and guides urgent therapy; the cholinergic signs, in particular, are useful bedside clues to counter-regulatory activation [38].

Placing hypoglycemia within the framework of normal postprandial physiology clarifies how dysregulation develops. Following a carbohydrate-rich meal, complex glucose polymers are enzymatically hydrolyzed in the oral cavity and small intestine to release free glucose. Enterocytes absorb this glucose across the apical membrane via sodium–glucose cotransporters (SGLTs), exploiting the inward sodium gradient. Glucose then exits across the basolateral membrane through facilitated diffusion mediated by GLUT transporters, entering the portal circulation and raising systemic glycemia. The ensuing rise in extracellular glucose is sensed by pancreatic β -cells, which rapidly secrete pre-formed insulin. Insulin orchestrates multiple downstream effects that dispose of the glucose surge: in hepatocytes it upregulates enzymes of glycogen synthesis, notably glycogen synthase, channeling glucose-6-phosphate into expanding glycogen stores; in skeletal muscle and adipose tissue it triggers translocation of GLUT-4 from intracellular vesicles to the plasma membrane, markedly increasing cellular glucose uptake and attenuating the postprandial peak. As plasma glucose recedes toward baseline, circulating insulin concentrations fall back into the low-normal range.

Should glucose fall below the physiologic set point—owing to delayed feeding, excess insulin or secretagogues, or heightened activity—the counter-regulatory axis is engaged. Diminished β -cell insulin output disinhibits pancreatic α -cells, prompting **glucagon** release. Glucagon restores plasma glucose by accelerating hepatic glycogenolysis and stimulating gluconeogenesis, typically providing sufficient substrate to bridge the interval until the next meal. With more prolonged caloric deprivation or deeper hypoglycemia, additional defenses are recruited: the adrenal axis increases **epinephrine** (and, via cortical activation, **cortisol**), further mobilizing hepatic glucose production, restraining insulin effects in peripheral tissues, and promoting lipolysis to supply gluconeogenic precursors. These layered responses ordinarily re-establish euglycemia; however, in patients exposed to potent glucose-lowering drugs, with impaired oral intake, or with blunted counter-regulatory signaling, the system can be overwhelmed, culminating in symptomatic or severe hypoglycemia that demands prompt recognition and treatment [14][39][40].

Conclusion:

Glucose physiology exemplifies an elegant, multilayered control system that balances immediate cellular energy needs with whole-body stability across fasting–feeding cycles, stress, illness, and exercise. At its core, ATP generation from glucose proceeds through modular pathways—glycolysis, pyruvate oxidation, the tricarboxylic acid cycle, and oxidative

phosphorylation—whose outputs scale with oxygen availability and tissue demand. This biochemical engine is supplied by an equally sophisticated logistics network: dietary intake and intestinal absorption via SGLTs, hepatic transformation and buffering through glycogenesis and glycogenolysis, and tissue delivery governed by GLUT isoforms, with GLUT-4 providing rapid, insulin-driven uptake in muscle and adipose tissue. Endocrine integration gives the system its resilience. Insulin coordinates storage and utilization after meals, while glucagon and catecholamines mobilize endogenous reserves during scarcity or acute stress; thyroid hormone, cortisol, growth hormone, and ACTH modulate the set-points and substrate selection that define day-to-day glycemic variability. These signals converge on the liver as the principal controller of glucose appearance, and on skeletal muscle and adipose tissue as the main sinks for glucose disposal. When any node falters— β -cell failure, insulin resistance, transporter dysfunction, or impaired counter-regulation—homeostasis degrades into dysglycemia.

Clinically, this framework clarifies why the same analyte—blood glucose—captures diverse disease states yet demands context-sensitive interpretation. Fasting blood glucose reflects basal hepatic output and insulin tone; random testing informs triage and symptomatic assessment; the oral glucose tolerance test probes the integrated postprandial response and unmasks early dysregulation. Linking mechanisms to measurement guides timely diagnosis of impaired glucose tolerance and diabetes, informs surveillance for microvascular and macrovascular injury, and anticipates acute decompensations such as hyperosmolar hyperglycemic state or treatment-induced hypoglycemia. For practitioners, the practical implications are threefold. First, pair test selection with the physiologic question at hand—basal versus dynamic control—and interpret results alongside nutritional status, medications, and comorbid stressors. Second, target therapies to the failing control points: restore insulin action (behavioral measures, pharmacotherapy), restrain hepatic glucose production, enhance peripheral uptake, and preserve β -cell function. Third, monitor for downstream organ damage while addressing modifiable cardiometabolic risks that compound glycemic injury. Mastery of these physiological principles equips clinicians to personalize prevention and treatment, reducing the burden of dysglycemia across settings and stages of disease.

References:

1. Yu EY, Ren Z, Mehrkanoon S, Stehouwer CDA, van Greevenbroek MMJ, Eussen SJPM, Zeegers MP, Wesselius A. Plasma metabolomic profiling of dietary patterns associated with glucose metabolism status: The Maastricht Study. *BMC Med.* 2022 Nov 21;20(1):450.
2. Remesar X, Alemany M. Dietary Energy Partition: The Central Role of Glucose. *Int J Mol Sci.* 2020 Oct 19;21(20)
3. Goyal MS, Raichle ME. Glucose Requirements of the Developing Human Brain. *J Pediatr Gastroenterol Nutr.* 2018 Jun;66 Suppl 3(Suppl 3):S46-S49.
4. Hui S, Ghergurovich JM, Morscher RJ, Jang C, Teng X, Lu W, Esparza LA, Reya T, Le Zhan, Yanxiang Guo J, White E, Rabinowitz JD. Glucose feeds the TCA cycle via circulating lactate. *Nature.* 2017 Nov 02;551(7678):115-118.
5. Liu S, Dai Z, Cooper DE, Kirsch DG, Locasale JW. Quantitative Analysis of the Physiological Contributions of Glucose to the TCA Cycle. *Cell Metab.* 2020 Oct 06;32(4):619-628.e21.
6. Gurung P, Zubair M, Jialal I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 27, 2024. Plasma Glucose.
7. Daghlis SA, Mohiuddin SS. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Biochemistry, Glycogen.
8. Kellett GL, Brot-Laroche E, Mace OJ, Leturque A. Sugar absorption in the intestine: the role of GLUT2. *Annu Rev Nutr.* 2008;28:35-54.
9. Fazakerley DJ, Koumanov F, Holman GD. GLUT4 On the move. *Biochem J.* 2022 Feb 11;479(3):445-462.
10. Holesh JE, Aslam S, Martin A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 12, 2023. Physiology, Carbohydrates.
11. Navale AM, Paranjape AN. Glucose transporters: physiological and pathological roles. *Biophys Rev.* 2016 Mar;8(1):5-9.
12. Srichaikul K, Jenkins DJA. The Glycemic Index, Rate of Digestion of Carbohydrate Foods, and Their Potential Link with Cardiovascular Disease. *J Nutr.* 2022 Apr 01;152(4):920-921.
13. Jones JG. Hepatic glucose and lipid metabolism. *Diabetologia.* 2016 Jun;59(6):1098-103.
14. El Sayed SA, Mukherjee S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Physiology, Pancreas.
15. Vargas E, Joy NV, Carrillo Sepulveda MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Sep 26, 2022. Biochemistry, Insulin Metabolic Effects.
16. Venugopal SK, Sankar P, Jialal I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 6, 2023. Physiology, Glucagon.
17. Dutt M, Wehrle CJ, Jialal I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Physiology, Adrenal Gland
18. Pirahanchi Y, Tariq MA, Jialal I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 13, 2023. Physiology, Thyroid.
19. Rawindraraj AD, Basit H, Jialal I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Physiology, Anterior Pituitary.
20. Christensen MB. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans. *Dan Med J.* 2016 Apr;63(4)
21. Kubihal S, Goyal A, Gupta Y, Khadgawat R. Glucose measurement in body fluids: A ready reckoner for clinicians. *Diabetes Metab Syndr.* 2021 Jan-Feb;15(1):45-53.
22. Murray-Bachmann R, Leung TM, Myers AK, Murthi S, Sarbanes M, Ziskovich K, Lesser M, Poretsky L. Reliability of continuous glucose monitoring system in the inpatient setting. *J Clin Transl Endocrinol.* 2021 Sep;25:100262.
23. Sung JF, Taslimi MM, Faig JC. Continuous glucose monitoring in pregnancy: new frontiers in clinical applications and research. *J Diabetes Sci Technol.* 2012 Nov 01;6(6):1478-85.
24. Chen ME, Aguirre RS, Hannon TS. Methods for Measuring Risk for Type 2 Diabetes in Youth: the Oral Glucose Tolerance Test (OGTT). *Curr Diab Rep.* 2018 Jun 16;18(8):51

25. Galant AL, Kaufman RC, Wilson JD. Glucose: Detection and analysis. *Food Chem.* 2015 Dec 01;188:149-60.
26. Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. *Medicina (Kaunas).* 2019 Aug 29;55(9)
27. Tonelli J, Kishore P, Lee DE, Hawkins M. The regulation of glucose effectiveness: how glucose modulates its own production. *Curr Opin Clin Nutr Metab Care.* 2005 Jul;8(4):450-6.
28. Kishimoto I. Subclinical Reactive Hypoglycemia with Low Glucose Effectiveness-Why We Cannot Stop Snacking despite Gaining Weight. *Metabolites.* 2023 Jun 15;13(6)
29. Karakas SE. Reactive Hypoglycemia: A Trigger for Nutrient-Induced Endocrine and Metabolic Responses in Polycystic Ovary Syndrome. *J Clin Med.* 2023 Nov 23;12(23)
30. Chao HW, Chao SW, Lin H, Ku HC, Cheng CF. Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease. *Int J Mol Sci.* 2019 Jan 13;20(2)
31. Harreiter J, Roden M. [Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023)]. *Wien Klin Wochenschr.* 2023 Jan;135(Suppl 1):7-17.
32. Nawale RB, Mourya VK, Bhise SB. Non-enzymatic glycation of proteins: a cause for complications in diabetes. *Indian J Biochem Biophys.* 2006 Dec;43(6):337-44.
33. Goyal R, Singhal M, Jialal I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 23, 2023. Type 2 Diabetes.
34. Goyal R, Nguyen M, Jialal I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 8, 2023. Glucose Intolerance.
35. Adeyinka A, Kondamudi NP. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 12, 2023. Hyperosmolar Hyperglycemic Syndrome.
36. Awosika A, Adabanya U, Millis RM, Omole AE, Moon JH. Postprandial Hypotension: An Underreported Silent Killer in the Aged. *Cureus.* 2023 Feb;15(2):e35411.
37. Morgan RK, Cortes Y, Murphy L. Pathophysiology and aetiology of hypoglycaemic crises. *J Small Anim Pract.* 2018 Nov;59(11):659-669.
38. Mathew P, Thoppil D. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 26, 2022. Hypoglycemia.
39. Kalra A, Yetiskul E, Wehrle CJ, Tuma F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Physiology, Liver.
40. International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. *Lancet Diabetes Endocrinol.* 2019 May;7(5):385-396